Skip to main content

Table 4 Two-year survival outcomes

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

  Relapse NRM LFS OS GRFS
PTCY 25.2% [18–32.9] 15.2% [9.7–21.8] 59.7% [50.6–67.6] 62.7% [53.4–70.7] 41.6% [33–50]
ATG 23.7% [21.4–26] 16.7% [14.8–18.8] 59.6% [56.8–62.2] 64.8% [62.1–67.4] 49.3% [46.6–52.1]
pvalue 0.6 0.6 0.97 0.95 0.2
  1. Abbreviations: ATG antithymocyte globulin, GRFS GVHD-free, relapse-free survival, LFS leukemia-free survival, OS overall survival, NRM non-relapse mortality, PTCY posttransplantation cyclophosphamide